Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAN-PCD: Idrevloride with/without Ivacaftor in PCD
NCT02871778Phase 2Completed
- Sponsor
- Parion Sciences
- Start
- Aug 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of idrevloride in primary ciliary dyskinesia (PCD) (8 arms), sponsored by Parion Sciences. Primary endpoints: Treatment Emergent Adverse Events at Day 113 and Percent Predicted Forced Expiratory Volume in 1 Second at Day 29. Started Aug 2016; status: completed.
02
Drugs
idrevloride
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on NCT02871778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871778.